GeneHealth - Your precision medicine

Phacolytic Glaucoma

Disease Details

Family Health Simplified

Buy Membership

Description: Phacolytic glaucoma is a type of secondary open-angle glaucoma caused by the leakage of high-molecular-weight lens proteins from a hypermature cataract, leading to trabecular meshwork obstruction and elevated intraocular pressure.
Type: Phacolytic glaucoma is not a genetically transmitted condition. It is a type of secondary glaucoma that occurs due to the leakage of lens proteins through an intact, but hypermature, lens capsule, often associated with cataracts.
Signs And Symptoms: There are a variety of characteristics which indicate that an individual may have phacolytic glaucoma. Within older people, the lens of the eye may appear to be yellow and lose its transparency (becomes cloudy). Once the protein begins to seep into the lens, permanent damage to the lens may be caused as the precipitate in lens impairs vision.
Another symptom includes the fading of visual clarity. This symptom makes the eye create an image commonly described to appear as though looking through a waterfall. If the lens becomes completely opaque the individual will become blind, even though the photoreceptor cells are completely functional. Other common symptoms include;

clouding of the eyes natural lens
increase in intraocular pressure, which lies behind the iris and the pupil
red eyes
acute onset pain
tearing
corneal edema
photophobia (experience of discomfort to the eyes because of the exposure of high levels of light or by presence of physical sensitivity within the eyes)
significantly decreased vision.The major influencers of this illness include high exposure to the sun and age as this is a rare condition for individuals under the age of 35.
Prognosis: Phacolytic glaucoma, a form of secondary open-angle glaucoma, occurs due to leakage of lens proteins from a hypermature cataract. The prognosis for phacolytic glaucoma largely depends on prompt diagnosis and appropriate treatment. If treated early with cataract extraction, intraocular pressure (IOP) typically returns to normal, and the prognosis is generally good. However, delayed treatment can lead to permanent optic nerve damage and significant vision loss.
Onset: Phacolytic glaucoma is characterized by an acute onset. The condition typically arises in elderly patients with hypermature cataracts, leading to the leakage of lens proteins into the aqueous humor, which subsequently causes an inflammatory response and elevated intraocular pressure.
Prevalence: Phacolytic glaucoma is a type of secondary open-angle glaucoma that occurs due to an inflammatory response to a hypermature cataract. The prevalence is relatively low, as it is seen more commonly in underdeveloped or developing regions where access to timely cataract surgery is limited. Specific prevalence data are not commonly detailed in the literature, highlighting its rarity in areas with advanced ophthalmic care.
Epidemiology: The youngest patient found to be diagnosed with Phacolytic Glaucoma was 35 years of age, which thereby highlights its significant prevalence in senior patients. Moreover, Phacolytic Glaucoma is more likely seen in underdeveloped countries as a result of the lack of access to ophthalmologic care. When being faced with Phacolytic Glaucoma most cases ameliorate when the cataract is extracted thereby enhancing vision. On the other hand, this disease is less prevalent in developed countries such as Australia and the United States, due to a greater access to health care and earlier cataract surgery.

== References ==
Intractability: Phacolytic glaucoma is not typically considered intractable. It is a secondary open-angle glaucoma caused by the leakage of lens proteins from a hypermature cataract, leading to an inflammatory response and increased intraocular pressure. Treatment usually involves managing the elevated intraocular pressure with medications and addressing the underlying cataract, often through cataract extraction surgery. Most patients experience significant improvement once the appropriate treatment is administered.
Disease Severity: **Phacolytic Glaucoma**

**Disease Severity:**
Phacolytic glaucoma is considered a severe form of secondary glaucoma. It occurs due to the leakage of lens proteins from a hypermature cataract, leading to inflammation and blockage of the trabecular meshwork, causing increased intraocular pressure. If not treated promptly, it can result in significant vision loss or blindness.
Healthcare Professionals: Disease Ontology ID - DOID:12570
Pathophysiology: Phacolytic glaucoma is a type of secondary open-angle glaucoma that occurs due to the leakage of lens proteins from a hypermature cataract. The pathophysiology involves the following key points:

1. **Lens Protein Leakage**: A hypermature cataract leads to the breakdown of the lens capsule, resulting in the leakage of high-molecular-weight lens proteins into the aqueous humor.

2. **Immune Response**: These leaked proteins are recognized as foreign by the body's immune system, leading to an inflammatory response. Macrophages are recruited to phagocytize the lens proteins.

3. **Trabecular Meshwork Obstruction**: The inflammatory response, along with the presence of lens proteins and phagocytizing macrophages, obstructs the trabecular meshwork. This impedes the outflow of aqueous humor from the anterior chamber.

4. **Increased Intraocular Pressure**: The obstruction of aqueous humor outflow results in increased intraocular pressure (IOP), causing glaucoma.

Elevated IOP can lead to optic nerve damage if not promptly managed, highlighting the need for timely intervention in cases of phacolytic glaucoma.
Carrier Status: Phacolytic glaucoma does not involve a carrier status as it is not a genetic condition. It occurs due to the leakage of lens protein through the intact lens capsule in eyes with hypermature cataracts, leading to an inflammatory response and increased intraocular pressure.
Mechanism: Phacolytic glaucoma is a type of secondary open-angle glaucoma resulting from the leakage of lens proteins through an intact but hypermature lens capsule.

**Mechanism:**
When the lens undergoes hypermaturity, proteins from the crystalline lens leak into the anterior chamber of the eye. These proteins provoke an inflammatory response, leading to:

1. Obstruction of the trabecular meshwork by macrophages that have ingested lens proteins.
2. Increased outflow resistance in the anterior chamber.
3. Elevated intraocular pressure (IOP) due to impaired aqueous humor drainage.

**Molecular Mechanisms:**
The key molecular processes involved include:

1. **Protein Aggregation and Leakage:**
- Hyperosmolarity within the hypermature lens facilitates protein aggregation.
- Proteins such as alpha-crystallin, beta-crystallin, and gamma-crystallin leak through the capsule.

2. **Inflammatory Response:**
- Lens proteins in the anterior chamber activate macrophages.
- Macrophages phagocytize (ingest) the leaked lens proteins and may themselves obstruct the trabecular meshwork.
- Inflammatory cytokines like TNF-α and IL-1β may be released, contributing to blockage and fibrosis in the outflow pathway.

3. **Role of Molecular Chaperones:**
- In normal conditions, small heat shock proteins (sHSPs) like HSP27 maintain lens protein solubility. In hypermature cataracts, this balance is disrupted, leading to protein precipitation and leakage.

Understanding these mechanisms helps in diagnosing and treating phacolytic glaucoma, often necessitating lens extraction to alleviate the increase of intraocular pressure.
Treatment: The procedure involved in the curing of phacolysis includes the reduction of intraocular pressure (IOP) in the eye followed by cataract extraction surgery. Medical management is commonly used simply to control the inflammation temporarily. The reduction of intraocular pressure can be conducted through the use of a combination of topical and systemic IOP-lowering agents, cycloplegics, aqueous suppressants, hyper-osmotic agents, and anti-inflammatory drugs. Topical steroids also may assist in lowering intraocular pressure and decreasing pain.Previous to cataract surgery a variety of optometrical tests have to be conducted to comprehensively analyse an individual's eye-sight prior to the surgery. A refraction is also conducted to determine how much nearsightedness, farsightedness and/or astigmatism an individual may have. Additional specific measurements of the eye will be necessary in order to determine the curvature and length of the cornea in order to choose the most effective IOL which will need to be inserted during the surgery.Cataract surgery has become a very simple process which, with modern-day technology, can be conducted in a local anaesthetic procedure in an average time period of 15 minutes. The aim of cataract surgery is to replace the lens within the eye with an artificial lens to clear vision while removing any residue which could cloud vision. The cataract extraction surgery involves four major steps which includes; local anaesthetic, clearing of eye, intraocular lens is inserted and finally the contact lens to protect the eye which dissolves releasing antibiotics.Before major advancements in medical technology, cuts had to be manually made to the lens to conduct cataract extraction surgery, however, with the improvements in technology the LASIK procedure is the main procedure used to conduct cataract surgeries. This procedure involves the use of femtosecond lasers which allow for precision cuts to create the corneal flap necessary to clear the cataract which were substituted for use instead of a surgical tool which is generally hand-held by the surgeon to conduct the same incision manually. The corneal incision, the anterior capsulotomy and lens and cataract fragmentation are steps in which can be an alternative. Within this process, lasers strike a titanium-like target that are attached to an irrigation-aspiration probe. It is said that the utilisation of this laser will enable for better precision, accuracy and reproducibility for the corneal incision, the anterior capsulotomy and lens and cataract, therefore ensuring the reduction of risks and enabling for refined visual development of phacolysis and the extraction of cataract.When completing the surgery the utilisation of laser cataract surgery will allow for a precise incision resulting in a self-sealing process, enabling for the reduction of infection after the surgery. Therefore, as a result of the advancements in which the laser cataract surgery has provided, regarding the removal of the lens, surgeons have been able to complete the procedure in a more efficient manner and thereby ensure an improvement in the outcomes for individuals suffering from phacolysis. Additionally, the laser cataract procedures which are used to cure phacolysis have a success rate of 98% further proving this procedure's effectiveness.The main issue with this technology is that the process costs about $300,000 to $500,000 and like all surgical procedures there is a degree of risk. Within the cataract removal procedures which take place a variety of complications may occur including;

chronic inflammation inside the eye
retinal detachment
infection
Compassionate Use Treatment: Phacolytic glaucoma typically results from the leakage of high-molecular-weight lens proteins through a hypermature cataract, causing an inflammatory response and secondary open-angle glaucoma. Due to the nature of this condition, definitive treatment often involves surgical intervention rather than pharmacological options.

1. **Compassionate Use Treatment:** This typically involves accessing investigational treatments when no other options are available, and the intervention must be approved by regulatory authorities. Given the surgical nature of phacolytic glaucoma management, compassionate use for drugs is less relevant here.

2. **Off-Label Treatments:** Off-label use of medications usually involves drugs that reduce intraocular pressure (IOP). While these are not specifically for phacolytic glaucoma, they can be used to manage symptoms until surgery can be performed. These may include:
- **Topical Beta-Blockers (e.g., Timolol):** To decrease aqueous humor production.
- **Alpha Agonists (e.g., Brimonidine):** To reduce IOP.
- **Carbonic Anhydrase Inhibitors (e.g., Dorzolamide):** To lower IOP by decreasing aqueous humor production.
- **Prostaglandin Analogues (e.g., Latanoprost):** To increase aqueous outflow.

3. **Experimental Treatments:** Research is ongoing in the field of ophthalmology, but surgical removal of the cataractous lens remains the standard and definitive treatment for phacolytic glaucoma. Experimental treatments are typically more focused on improving surgical techniques or postoperative recovery rather than pharmaceutical management of the condition.

Given the acute nature of phacolytic glaucoma, prompt surgical intervention is critical. The use of anti-glaucoma medications can help manage intraocular pressure temporarily before definitive surgery.
Lifestyle Recommendations: Phacolytic glaucoma is a type of secondary open-angle glaucoma that occurs due to the leakage of lens proteins from a hypermature cataract. While it is primarily managed medically and surgically, certain lifestyle recommendations can support overall eye health and potentially aid in the management of glaucoma:

1. **Regular Eye Exams**: Frequent check-ups with an ophthalmologist are crucial for monitoring eye pressure and overall eye health.
2. **Medication Adherence**: Strictly follow prescribed medications and treatment plans.
3. **Healthy Diet**: Consume a diet rich in fruits and vegetables, particularly those high in antioxidants like leafy greens and colorful veggies.
4. **Physical Activity**: Engage in regular, moderate exercise to improve overall health and circulation.
5. **Hydration**: Maintain adequate fluid intake, but avoid excessive intake of large amounts of fluid in a short period, as it can increase eye pressure.
6. **Stress Management**: Practice stress-relief techniques such as mindfulness, yoga, and deep-breathing exercises.
7. **Avoid Smoking**: Smoking can worsen eye health and is linked to several eye diseases.
8. **Limit Caffeine**: High levels of caffeine can transiently increase eye pressure.
9. **Sleep Position**: Avoid sleeping with your head flat; use pillows to elevate your head slightly to reduce eye pressure overnight.
10. **Protect Your Eyes**: Use protective eyewear to prevent eye injuries and reduce stress on the eyes.

Always consult with a healthcare provider to tailor recommendations to your specific condition.
Medication: It is found that with most cases, of phacolytic glaucoma post surgery patients are not exposed to many further obstacles in the healing process which therefore avoids the need for medication. Although, it is mostly encouraged that patients take antiglaucoma medication in order to deter the possibility of glaucoma and inflammation implicating the eye. One of these medications include eye drops which contain prostaglandin analogs. Prostaglandin analogs aim to lower intraocular pressure which thereby avoids inflammation to ensure an efficient healing process after cataract removal. Carbonic anhydrase inhibitors (CAI) in the form of pills, disables the production of the sodium pump in the aqueous humor and thereby decreases inflammation to, in turn, lower intraocular pressure.

The only major obstacle which could affect the healing process after the surgery necessary to treat phacolytic glaucoma would be an infection to the eye. The ophthalmologists' conducting the surgery must aim to reduce the amount of microbes which are present on the ocular surface and avoid intracocular contamination during the procedure. These tasks can be conducted through the use of intracameral and topical antibiotics. Intracameral antibiotics are usually injections which are put into the eye or ocular surface to rid of microbes. Topical antibiotics come in the form of tablets which can be consumed through the mouth to treat bacterial infection. The use of either or both are left to the surgeon and their personal opinion on the possibility of bacterial infection.
Repurposable Drugs: Phacolytic glaucoma is a type of secondary open-angle glaucoma that occurs due to the leakage of high-molecular-weight proteins from a hypermature cataract into the anterior chamber, causing an inflammatory response and increased intraocular pressure. Treatment for phacolytic glaucoma typically focuses on managing intraocular pressure and addressing the underlying cataract.

Currently, there are no explicitly recognized repurposable drugs for phacolytic glaucoma. The main treatment approaches usually involve:

1. **Medications**: Topical aqueous suppressants (e.g., beta-blockers, carbonic anhydrase inhibitors, alpha agonists) and hyperosmotic agents (e.g., oral glycerin or intravenous mannitol) to lower intraocular pressure temporarily.
2. **Corticosteroids**: These can help reduce inflammation in the eye.
3. **Surgery**: Definitive treatment involves cataract extraction to remove the source of the leaked proteins.

Before using any treatment, it’s essential to consult an ophthalmologist.
Metabolites: Phacolytic glaucoma is a type of secondary open-angle glaucoma caused by the leakage of high-molecular-weight lens proteins from a hypermature cataract into the anterior chamber, which obstructs the aqueous outflow. Specific metabolites are not primarily involved in this condition; the focus is on the protein leakage rather than metabolic by-products.
Nutraceuticals: There is no established evidence or widely accepted practice for using nutraceuticals in the treatment or management of phacolytic glaucoma. Phacolytic glaucoma is primarily managed through ophthalmic interventions, which may include medications to lower intraocular pressure and surgical procedures to remove the cataract causing the issue. It is important to consult with an ophthalmologist for appropriate diagnosis and treatment.
Peptides: Phacolytic glaucoma is not typically treated with peptides. It is an eye condition caused by the leakage of lens proteins through a hypermature cataract, leading to an inflammatory response and increased intraocular pressure. The standard treatment typically involves addressing the underlying cataract, often through cataract surgery.

Regarding nanoparticles (nan), research into nanotechnology for ophthalmic applications is ongoing, but it is not a standard treatment for phacolytic glaucoma. The use of nanotechnology in glaucoma primarily focuses on improved drug delivery systems to enhance the efficacy of existing treatments.